SCHEMBL428159

SCHEMBL428159

Brc1cccc2ncccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.58
KDM4E B2RXH2 2/20 0.58
GRM5 P41594 1/20 0.49
KCNH2 Q12809 1/20 0.49
POLB P06746 1/20 0.48
BACE1 P56817 1/20 0.48
CYP3A4 P08684 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
ALDH1A1 P00352 3/20 0.46
APAF1 O14727 2/20 0.46
TDP2 O95551 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
HTT P42858 4/20 0.45
LMNA P02545 3/20 0.45
HSP90AA1 P07900 2/20 0.45
HSP90AB1 P08238 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29662059 1.00 MAPT (0.58) MAPTKDM4EGRM5KCNH2POLB
SCHEMBL14127412 1.00 MAPT (0.58) MAPTKDM4EGRM5KCNH2POLB
SCHEMBL29923695 0.84 NCF1 (0.56) MAPTKDM4EGRM5KCNH2CYP3A4
SCHEMBL244384 0.84 NCF1 (0.56) MAPTKDM4EGRM5KCNH2CYP3A4
SCHEMBL9376922 0.83 HTT (0.53) MAPTKDM4EGRM5KCNH2POLB
SCHEMBL6180305 0.83 CYP19A1 (0.47) MAPTKDM4EGRM5KCNH2POLB
SCHEMBL27297374 0.83 CYP3A4 (0.50) MAPTKDM4EGRM5KCNH2POLB
SCHEMBL30976614 0.82 NCF1 (0.54) MAPTKDM4EGRM5KCNH2CYP3A4
SCHEMBL8347393 0.79 MAPT (0.50) MAPTKDM4EPOLBCYP3A4MEN1
Formaldehyde SCHEMBL28759854 0.78 NCF1 (0.50) MAPTKDM4EGRM5KCNH2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 744 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116102494-B Triphenylamine derivative and preparation method thereof, photochromic thin-film material and preparation method and application thereof 广东工业大学 2025-06-03 CN claimed
CN-114105984-B Method for preparing indolizine type corrosion inhibitor 中国石油大学(华东) 2023-08-25 CN claimed
CN-112250628-B Method for preparing tetrahydroquinoline compound by catalytic hydrogenation of ruthenium catalyst 上海应用技术大学 2022-07-08 CN claimed
CN-110229102-B 2-alkylated quinoline, derivative and synthetic method thereof 湘潭大学 2022-05-17 CN claimed
CN-112375037-B Synthetic method of 3-amino-5-bromoquinoline 苏州康润医药有限公司 2022-04-12 CN claimed
CN-114105984-A Preparation method of indolizine corrosion inhibitor 中国石油大学(华东) 2022-03-01 CN claimed
CN-114014858-A Process for preparing polysubstituted indolizine derivatives 淮阴师范学院 2022-02-08 CN claimed
CN-111334066-B 640nm excited near-infrared fluorescent dye and preparation method thereof 中国科学院大连化学物理研究所 2021-12-10 CN claimed
CN-112375037-A Synthetic method of 3-amino-5-bromoquinoline 苏州康润医药有限公司 2021-02-19 CN claimed
CN-112250628-A Method for preparing tetrahydroquinoline compound by catalytic hydrogenation of ruthenium catalyst 上海应用技术大学 2021-01-22 CN claimed
CN-111334066-A 640nm excited near-infrared fluorescent dye and preparation method thereof 中国科学院大连化学物理研究所 2020-06-26 CN claimed
CN-110229102-A 2- is alkylated quinoline, derivative and its synthetic method 湘潭大学 2019-09-13 CN claimed
WO-2015095305-A1 PRODUCTION OF CYCLIC PHOSPHATE, PHOSPHORAMIDATE, THIOPHOSPHATE, AND PHOSPHONATE NUCLEOSIDE COMPOUNDS IDENIX PHARMACEUTICALS, INC. (US) 2015-06-25 WO claimed
US-6541487-B1 Administering 5-bromoquinoline, 5-nitroisoquinoline, 8-nitroisoquinoline, 3,4-dihydro-6-hydroxy-2(1H)-quinolone or 1-methylisoquinoline to relax corpus cavernosa smooth-muscle tissue in males or females R.T. ALAMO VENTURES I, LLC 2003-04-01 US claimed
WO-2002019997-A1 PDE III INHIBITORS FOR TREATING SEXUAL DYSFUNCTION CUTLER NEAL R (US) 2002-03-14 WO claimed
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2026-05-21 US disclosed
EP-4743457-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE 4M THERAPEUTICS INC. (US) 2026-05-20 EP disclosed
EP-0326328-A2 Quinoline, quinazoline, and cinnoline derivatives DowElanco (US) 1989-08-02 EP disclosed
US-4396620-A BACTERICIDES ELI LILLY AND COMPANY (US) 1983-08-02 US disclosed
US-4382931-A 3'-Substituted quinolinium cephalosporins ELI LILLY AND COMPANY (US) 1983-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM5, CHRM3 MAPT 2127/4885KDM4E 3909/4885GRM5 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.